P

Pfizer

Makes cancer drugs, vaccines and other medicines

Field Reimbursement Manager 1

Full-TimePosted on 10/16/2026Deadline 10/23/26
$139.1k - $231.9k/yr
Senior
Bachelor's
Remote in USA+1 moreMore locations: Memphis, TN, USA
RemoteUnited States (remote): Must reside in or within commutable distance to territory boundaries.
Customer Experience & Support
No H1B Sponsorship

About the job

Requirements
  • At least 7 years of pharmaceutical industry experience, typically in pharmaceutical sales and/or coding and reimbursement.
  • A B.S. or B.A. degree is required.
  • Demonstrated communication and presentation skills, strategic planning, successful plan implementation, leadership, and ability to work across internal boundaries and collaborate with relevant stakeholders.
  • Ability to work in a highly regulated environment and follow company compliance guidelines and procedures.
  • A proven track record of broad collaboration with diverse customers, clients, and stakeholders.
  • Training in and experience with responsible business communication, both written and spoken.
  • A valid U.S. driver's license and a driving record that complies with company standards.
  • Ability to influence and collaborate with peers, develop and coach others, and oversee and guide colleagues' work to achieve outcomes.
  • Must reside in or within commuting distance of territory boundaries.
Responsibilities
  • Conduct office calls with health care providers and office staff who need support to enable appropriate patient access to Pfizer products, including resolving reimbursement and coverage questions.
  • Provide in-person and virtual education to health care providers and office staff on local and regional payer landscapes, payer coverage and formulary updates, payer policies such as prior authorization, step edits, and specialty pharmacy coverage, and patient support.
  • Distribute approved Pfizer materials to health care providers and office staff on coverage and reimbursement, including patient assistance programs and billing and coding reference guides.
  • Educate health care providers and office staff on Hub financial assistance offerings, enrollment processes, Hub provider portals, and other Hub financial assistance materials.
  • Coordinate with Pfizer patient access and support programs (Hubs) as needed to understand payer requirements for individual patients.
  • Address questions about the prescription status of patients enrolled in Pfizer patient access and support programs.
  • Use Pfizer's designated case notes system in compliance with company requirements.
  • Serve as the subject matter expert on reimbursement and coverage issues affecting Pfizer products in assigned regions and use that expertise to facilitate appropriate patient access to prescribed Pfizer products.
  • Provide internal Pfizer leadership with interpretive information and local market insights, as needed, about the impact of potential reimbursement issues.
  • Communicate with stakeholders in a compliant manner to influence adoption of ideas, actions, or positions through logical and engaging messages without direct authority.
  • Link customer insights to offerings and resources that address patient access barriers.
  • Build trust through follow-up and knowledge of the patient access journey.
  • Maintain discretion and confidentiality and adhere to company compliance guidelines and procedures.
  • Conduct live customer interactions, with an approximately 50% travel requirement.
Desired Qualifications
  • Reimbursement and access experience is a plus.
  • A strong understanding of specialty drug reimbursement, government payment systems, provider and carrier networks, co-pay assistance programs, and policy dynamics across Pfizer business units and brands.
  • Additional certification in coding and reimbursement is preferred but not required.
  • Coding and billing knowledge or certification is a plus but not required.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.